{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T09:00:50Z","timestamp":1790154050596,"version":"4.0.1"},"reference-count":69,"publisher":"BioExcel","license":[{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Alexion Pharma Spain S.L., AstraZeneca Rare Disease"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DIC"],"abstract":"<jats:p>This report summarizes expert and patient-representative perspectives from the meeting entitled \u2018Standalone NF1: guiding the transition from paediatric to adult care\u2019, held in Madrid on October 2, 2025. Its primary objective was to examine clinical, organizational and patient- related challenges during transition and identify practical measures to improve continuity of care. Discussions focused on multidisciplinary co-ordination, case management, patient autonomy and structured transition pathways. NF1 characteristics, plexiform neurofibroma burden, surgery, and the currently approved MEK inhibitors selumetinib and mirdametinib, are summarized only for clinical context; selumetinib is discussed in greater detail because it was the treatment available at that time and the one addressed during the meeting.\n\nDownload the Plain Language Summary of this article: https:\/\/www.drugsincontext.com\/plain-language-summaries\/plain-language-summary-standalone-nf1-guiding-the-transition-from-paediatric-to-adult-care<\/jats:p>","DOI":"10.7573\/dic.2026-6-6","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T08:04:54Z","timestamp":1790150694000},"page":"1","source":"Crossref","is-referenced-by-count":0,"title":["Standalone NF1: guiding the transition from paediatric to adult care"],"prefix":"10.7573","author":[{"given":"H\u00e9ctor","family":"Salvador","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/001jx2139","id-type":"ROR","asserted-by":"publisher"}],"name":"Hospital Sant Joan de D\u00e9u Barcelona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1lvaro","family":"Lassaletta","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/028brk668","id-type":"ROR","asserted-by":"publisher"}],"name":"Hospital Infantil Universitario Ni\u00f1o Jes\u00fas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carlos","family":"L\u00f3pez-Guti\u00e9rrez","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01s1q0w69","id-type":"ROR","asserted-by":"publisher"}],"name":"Hospital Universitario La Paz"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Cucurull","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04wxdxa47","id-type":"ROR","asserted-by":"publisher"}],"name":"Hospital Universitari Germans Trias i Pujol"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Blanco","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04wxdxa47","id-type":"ROR","asserted-by":"publisher"}],"name":"Hospital Universitari Germans Trias i Pujol"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10047","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"1.\tOrraca M, Morej\u00f3n G, Cabrera N, Men\u00e9ndez R, Orraca O. Neurofibromatosis 1 prevalence in children aged 9\u201311 years, Pinar del Rio Province, Cuba. MEDICC Rev. 2014;16:22\u201326. https:\/\/doi.org\/10.37757\/MR2014.V16.N3-4.6","DOI":"10.37757\/MR2014.V16.N3-4.6"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"2.\tPoyhonen M, Kytola S, Leisti J. Epidemiology of neurofibromatosis type 1 (NF1) in Northern Finland. J Med Genet. 2000;37:632\u2013636. https:\/\/doi.org\/10.1136\/jmg.37.8.632","DOI":"10.1136\/jmg.37.8.632"},{"key":"ref2","unstructured":"3.\tLegius E, Messiaen L, Wolkenstein P, et al. Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation. Genet Med. 2021;23:1506\u20131513. https:\/\/doi.org\/10.1038\/ s41436-021-01170-5"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"4.\tDagalakis U, Lodish M, Dombi E, et al. Puberty and plexiform neurofibroma tumor growth in patients with neurofibromatosis type I. J Pediatr. 2014;164:620\u2013624. https:\/\/doi.org\/10.1016\/j.jpeds.2013.10.081","DOI":"10.1016\/j.jpeds.2013.10.081"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"5.\tKotch C, Dombi E, Shah AC, et al. Retrospective cohort analysis of the impact of puberty on plexiform neurofibroma growth in patients with neurofibromatosis type 1. J Pediatr. 2023;260:113513. https:\/\/doi.org\/10.1016\/ j.jpeds.2023.113513","DOI":"10.1016\/j.jpeds.2023.113513"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"6.\tBlakeley JO, Plotkin SR. Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosis. Neuro-Oncology. 2016;18:624\u2013638. https:\/\/doi.org\/10.1093\/neuonc\/nov200","DOI":"10.1093\/neuonc\/nov200"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"7.\tYap YS, McPherson JR, Ong CK, et al. The NF1 gene revisited \u2014 from bench to bedside. Oncotarget. 2014;5:5873\u2013 5892. https:\/\/doi.org\/10.18632\/oncotarget.2194","DOI":"10.18632\/oncotarget.2194"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"8.\tKorf BR. Neurofibromatosis. Handb Clin Neurol. 2013;111:333\u2013340. https:\/\/doi.org\/10.1016\/B978-0-444-52891-9.00039-7","DOI":"10.1016\/B978-0-444-52891-9.00039-7"},{"key":"ref8","unstructured":"9.\tFriedman JM. Neurofibromatosis 1. GeneReviews\u00ae. 2025. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1109\/. Accessed August 3, 2026."},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"10.\tRasmussen SA, Friedman JM. NF1 gene and neurofibromatosis 1. Am J Epidemiol. 2000;151:33\u201340. https:\/\/doi.org\/ 10.1093\/oxfordjournals.aje.a010118","DOI":"10.1093\/oxfordjournals.aje.a010118"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"11.\tListernick R, Ferner RE, Liu GT, et al. Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations. Ann Neurol. 2007;61:189\u2013198. https:\/\/doi.org\/10.1002\/ana.21107","DOI":"10.1002\/ana.21107"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"12.\tTonsgard JH. Clinical manifestations and management of neurofibromatosis type 1. Semin Pediatr Neurol. 2006;13:2\u20137. https:\/\/doi.org\/10.1016\/j.spen.2006.01.005","DOI":"10.1016\/j.spen.2006.01.005"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"13.\tLy I, Romo CG, Gottesman S, et al. Target product profile for cutaneous neurofibromas: clinical trials to prevent, arrest, or regress cutaneous neurofibromas. J Invest Dermatol. 2023;143:1388\u20131396. https:\/\/doi.org\/10.1016\/ j.jid.2023.01.041","DOI":"10.1016\/j.jid.2023.01.041"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"14.\tKim A, Stewart DR, Reilly KM, Viskochil D, Miettinen MM, Widemann BC. Malignant peripheral nerve sheath tumors state of the science: leveraging clinical and biological insights into effective therapies. Sarcoma. 2017;2017:7429697. https:\/\/doi.org\/10.1155\/2017\/7429697","DOI":"10.1155\/2017\/7429697"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"15.\tFlores Pimentel M, Heath A, Wan MJ, et al. Prevalence of choroidal abnormalities and Lisch nodules in children meeting clinical and molecular diagnosis of neurofibromatosis type 1. Transl Vis Sci Technol. 2022;11:10. https:\/\/doi.org\/ 10.1167\/tvst.11.2.10","DOI":"10.1167\/tvst.11.2.10"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"16.\tFerner RE, Huson SM, Thomas N, et al. Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J Med Genet. 2007;44:81\u201388. https:\/\/doi.org\/10.1136\/jmg.2006.045906","DOI":"10.1136\/jmg.2006.045906"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"17.\tEvans DGR, Salvador H, Chang VY, et al. Cancer and central nervous system tumor surveillance in pediatric neurofibromatosis 1. Clin Cancer Res. 2017;23:e46\u2013e53. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-0589","DOI":"10.1158\/1078-0432.CCR-17-0589"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"18.\tHirbe AC, Gutmann DH. Neurofibromatosis type 1: a multidisciplinary approach to care. Lancet Neurol. 2014;13:834\u2013 843. https:\/\/doi.org\/10.1016\/S1474-4422(14)70063-8","DOI":"10.1016\/S1474-4422(14)70063-8"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"19.\tMiller DT, Freedenberg D, Schorry E, et al. Health supervision for children with neurofibromatosis type 1. Pediatrics. 2019;143:e20190660. https:\/\/doi.org\/10.1542\/peds.2019-0660","DOI":"10.1542\/peds.2019-0660"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"20.\tBergqvist C, Servy A, Valeyrie-Allanore L, et al. Neurofibromatosis 1 French national guidelines based on an extensive literature review since 1966. Orphanet J Rare Dis. 2020;15:37. https:\/\/doi.org\/10.1186\/s13023-020-1310-3","DOI":"10.1186\/s13023-020-1310-3"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"21.\tFisher MJ, Blakeley JO, Weiss BD, et al. Management of neurofibromatosis type 1-associated plexiform neurofibromas. Neuro-Oncology. 2022;24:1827\u20131844. https:\/\/doi.org\/10.1093\/neuonc\/noac146","DOI":"10.1093\/neuonc\/noac146"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"22.\tRadomska KJ, Topilko P. Boundary cap cells in development and disease. Curr Opin Neurobiol. 2017;47:209\u2013215. https:\/\/doi.org\/10.1016\/j.conb.2017.11.003","DOI":"10.1016\/j.conb.2017.11.003"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"23.\tNguyen R, Kluwe L, Fuensterer C, et al. Plexiform neurofibromas in children with neurofibromatosis type 1: frequency and associated clinical deficits. J Pediatr. 2011;159:652\u2013655.e2. https:\/\/doi.org\/10.1016\/j.jpeds.2011.04.008","DOI":"10.1016\/j.jpeds.2011.04.008"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"24.\tAkshintala S, Baldwin A, Liewehr DJ, et al. Longitudinal evaluation of peripheral nerve sheath tumors in neurofibromatosis type 1: growth analysis of plexiform neurofibromas and distinct nodular lesions. Neuro- Oncology. 2020;22:1368\u20131378. https:\/\/doi.org\/10.1093\/neuonc\/noaa053","DOI":"10.1093\/neuonc\/noaa053"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"25.\tCollins-Sawaragi YC, Ferner R, Vassallo G, et al. Location, symptoms, and management of plexiform neurofibromas in 127 children with neurofibromatosis 1, attending the National Complex Neurofibromatosis 1 service, 2018\u20132019. Am J Med Genet A. 2022;188:1723\u20131727. https:\/\/doi.org\/10.1002\/ajmg.a.62691","DOI":"10.1002\/ajmg.a.62691"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"26.\tGross AM, Singh G, Akshintala S, et al. Association of plexiform neurofibroma volume changes and development of clinical morbidities in neurofibromatosis 1. Neuro-Oncology. 2018;20:1643\u20131651. https:\/\/doi.org\/10.1093\/neuonc\/ noy067","DOI":"10.1093\/neuonc\/noy067"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"27.\tPrada CE, Rangwala FA, Martin LJ, et al. Pediatric plexiform neurofibromas: impact on morbidity and mortality in neurofibromatosis type 1. J Pediatr. 2012;160:461\u2013467. https:\/\/doi.org\/10.1016\/j.jpeds.2011.08.051","DOI":"10.1016\/j.jpeds.2011.08.051"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"28.\tYang X, Yoo HK, Amin S, et al. Burden among caregivers of pediatric patients with neurofibromatosis type 1 (NF1) and plexiform neurofibroma (PN) in the United States: a cross-sectional study. Neurol Ther. 2022;11:1221\u20131233. https:\/\/doi.org\/10.1007\/s40120-022-00365-5","DOI":"10.1007\/s40120-022-00365-5"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"29.\tRietman AB, van Helden H, Both PH, et al. Worries and needs of adults and parents of adults with neurofibromatosis type 1. Am J Med Genet A. 2018;176:1150\u20131160. https:\/\/doi.org\/10.1002\/ajmg.a.38680","DOI":"10.1002\/ajmg.a.38680"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"30.\tKjaer TK, Andersen EW, Olsen M, et al. Forming and ending marital or cohabiting relationships in a Danish population-based cohort of individuals with neurofibromatosis 1. Eur J Hum Genet. 2020;28:1028\u20131033. https:\/\/doi.org\/ 10.1038\/s41431-020-0645-5","DOI":"10.1038\/s41431-020-0645-5"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"31.\tCohen JS, Levy HP, Sloan J, et al. Depression among adults with neurofibromatosis type 1: prevalence and impact on quality of life. Clin Genet. 2015;88:425\u2013430. https:\/\/doi.org\/10.1111\/cge.12551","DOI":"10.1111\/cge.12551"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"32.\tKongkriangkai AM, King C, Martin LJ, et al. Substantial pain burden in frequency, intensity, interference and chronicity among children and adults with neurofibromatosis type 1. Am J Med Genet A. 2019;179:602\u2013607. https:\/\/ doi.org\/10.1002\/ajmg.a.61069","DOI":"10.1002\/ajmg.a.61069"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"33.\tLy KI, Merker VL, Cai W, et al. Ten-year follow-up of internal neurofibroma growth behavior in adult patients with neurofibromatosis type 1 using whole-body MRI. Neurology. 2023;100:e661\u2013e670. https:\/\/doi.org\/10.1212\/ WNL.0000000000201535","DOI":"10.1212\/WNL.0000000000201535"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"34.\tEvans DG, Baser ME, McGaughran J, Sharif S, Howard E, Moran A. Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet. 2002;39:311\u2013314. https:\/\/doi.org\/10.1136\/jmg.39.5.311","DOI":"10.1136\/jmg.39.5.311"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"35.\tCarton C, Evans DG, Blanco I, et al. ERN GENTURIS tumour surveillance guidelines for individuals with neurofibromatosis type 1. EClinicalMedicine. 2023;56:101818. https:\/\/doi.org\/10.1016\/j.eclinm.2022.101818","DOI":"10.1016\/j.eclinm.2022.101818"},{"key":"ref35","unstructured":"36.\tGuill\u00e9n Navarro E, Ballesta Mart\u00ednez MJ, Gal\u00e1n G\u00f3mez E. Protocolo de seguimiento de la neurofibromatosis tipo 1. Protoc Diagn Ter Pediatr. 2010;1:44\u201350."},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"37.\tWolters PL, Burns KM, Martin S, et al. Pain interference in youth with neurofibromatosis type 1 and plexiform neurofibromas and relation to disease severity, social-emotional functioning, and quality of life. Am J Med Genet A. 2015;167A:2103\u20132113. https:\/\/doi.org\/10.1002\/ajmg.a.37123","DOI":"10.1002\/ajmg.a.37123"},{"key":"ref37","unstructured":"38.\tAnderson JL, Gutmann DH. Neurofibromatosis type 1. Handb Clin Neurol. 2015;132:75\u201386. https:\/\/doi.org\/10.1016\/ B978-0-444-62702-5.00004-4"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"39.\tNeedle MN, Cnaan A, Dattilo J, et al. Prognostic signs in the surgical management of plexiform neurofibroma: the Children\u2019s Hospital of Philadelphia experience, 1974\u20131994. J Pediatr. 1997;131:678\u2013682. https:\/\/doi.org\/10.1016\/s0022- 3476(97)70092-1","DOI":"10.1016\/S0022-3476(97)70092-1"},{"key":"ref39","unstructured":"40.\tFood and Drug Administration. FDA approves selumetinib for adults with neurofibromatosis type 1 with symptomatic, inoperable plexiform neurofibromas. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-selumetinib-adults-neurofibromatosis-type-1-symptomatic-inoperable-plexiform. Accessed August 3, 2026."},{"key":"ref40","unstructured":"41.\tFood and Drug Administration. FDA approves selumetinib for pediatric patients 1 year of age and older with neurofibromatosis type 1 with symptomatic, inoperable plexiform neurofibromas. https:\/\/www.fda.gov\/drugs\/ resources-information-approved-drugs\/fda-approves-selumetinib-pediatric-patients-1-year-age-and-older-neurofibromatosis-type-1. Accessed August 3, 2026."},{"key":"ref41","unstructured":"42.\tUS Food and Drug Administration. Orphan Drug Designations and Approvals: selumetinib. https:\/\/www. accessdata.fda.gov\/scripts\/opdlisting\/oopd\/detailedIndex.cfm?cfgridkey=624017. Accessed August 3, 2026."},{"key":"ref42","unstructured":"43.\tEuropean Medicines Agency. Koselugo (selumetinib). https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/ koselugo. Accessed August 3, 2026."},{"key":"ref43","unstructured":"44.\tEuropean Medicines Agency. Koselugo (selumetinib) \u2013 opinion on variation to marketing authorisation. https:\/\/ www.ema.europa.eu\/en\/medicines\/human\/variation\/koselugo. Accessed August 3, 2026."},{"key":"ref44","unstructured":"45.\tFood and Drug Administration. FDA approves mirdametinib for adult and pediatric patients with neurofibromatosis type 1 who have symptomatic plexiform neurofibromas not amenable to complete resection. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-mirdametinib-adult-and-pediatric-patients-neurofibromatosis-type-1-who-have-symptomatic. Accessed August 3, 2026."},{"key":"ref45","unstructured":"46.\tEuropean Medicines Agency. Ezmekly (mirdametinib). https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/ ezmekly. Accessed August 3, 2026."},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"47.\tAdeyemi A, Gross AM, Baldwin A, et al. Selumetinib in pediatric patients with neurofibromatosis type 1 and plexiform neurofibroma: propensity score analysis of SPRINT vs. natural history control arm. Neurooncol Adv. 2025;7:vdaf101. https:\/\/doi.org\/10.1093\/noajnl\/vdaf101","DOI":"10.1093\/noajnl\/vdaf101"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"48.\tDombi E, Baldwin A, Marcus LJ, et al. Activity of selumetinib in neurofibromatosis type 1-related plexiform neurofibromas. N Engl J Med. 2016;375:2550\u20132560. https:\/\/doi.org\/10.1056\/NEJMoa1605943","DOI":"10.1056\/NEJMoa1605943"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"49.\tWu PK, Park JI. MEK1\/2 inhibitors: molecular activity and resistance mechanisms. Semin Oncol. 2015;42:849\u2013862. https:\/\/doi.org\/10.1053\/j.seminoncol.2015.09.023","DOI":"10.1053\/j.seminoncol.2015.09.023"},{"key":"ref49","unstructured":"50.\tEuropean Medicines Agency. Summary of product characteristics: koselugo (selumetinib). https:\/\/www.ema. europa.eu\/en\/documents\/product-information\/koselugo-epar-product-information_en.pdf. Accessed August 3, 2026."},{"key":"ref50","unstructured":"51.\tFood and Drug Administration. Koselugo (selumetinib) prescribing information. https:\/\/www.accessdata.fda.gov\/ drugsatfda_docs\/label\/2025\/219943s002lbl.pdf. Accessed August 3, 2026."},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"52.\tGross AM, Wolters PL, Dombi E, et al. Selumetinib in children with inoperable plexiform neurofibromas. N Engl J Med. 2020;382:1430\u20131442. https:\/\/doi.org\/10.1056\/NEJMoa1912735","DOI":"10.1056\/NEJMoa1912735"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"53.\tGross AM, Dombi E, Wolters PL, et al. Long-term safety and efficacy of selumetinib in children with neurofibromatosis type 1 on a phase 1\/2 trial for inoperable plexiform neurofibromas. Neuro-Oncology. 2023;25:1883\u20131894. https:\/\/doi.org\/10.1093\/neuonc\/noad086","DOI":"10.1093\/neuonc\/noad086"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"54.\tGross AM, O\u2019Sullivan Coyne G, Dombi E, et al. Selumetinib in adults with NF1 and inoperable plexiform neurofibroma: a phase 2 trial. Nat Med. 2025;31:105\u2013115. https:\/\/doi.org\/10.1038\/s41591-024-03361-4","DOI":"10.1038\/s41591-024-03361-4"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"55.\tChen AP, Coyne GO, Wolters PL, et al. Efficacy and safety of selumetinib in adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas (KOMET): a multicentre, international, randomised, placebo-controlled, parallel, double-blind, phase 3 study. Lancet. 2025;405:2217\u20132230. https:\/\/doi.org\/10.1016\/S0140- 6736(25)00986-9","DOI":"10.1016\/S0140-6736(25)00986-9"},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"56.\tAzizi AA, Hargrave D, Passos J, et al. Consensus recommendations on management of selumetinib-associated adverse events in pediatric patients with neurofibromatosis type 1 and plexiform neurofibromas. Neurooncol Pract. 2024;11:515\u2013531. https:\/\/doi.org\/10.1093\/nop\/npae038","DOI":"10.1093\/nop\/npae038"},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"57.\tJackson S, Baker EH, Gross AM, et al. The MEK inhibitor selumetinib reduces spinal neurofibroma burden in patients with NF1 and plexiform neurofibromas. Neurooncol Adv. 2020;2:vdaa095. https:\/\/doi.org\/10.1093\/noajnl\/vdaa095","DOI":"10.1093\/noajnl\/vdaa095"},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"58.\tPassos J, Soares MP, Salgado D, et al. A single-center case study series assessing the effect of selumetinib use in patients with neurofibromatosis-related plexiform neurofibromas. Neurooncol Adv. 2024;6:vdae177. https:\/\/ doi.org\/10.1093\/noajnl\/vdae177","DOI":"10.1093\/noajnl\/vdae177"},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"59.\tSantoro C, Servedio M, Diana MC, et al. Real-world experience with selumetinib in children with neurofibromatosis type 1: a multicentric retrospective study. J Neurooncol. 2025;175:1027\u20131037. https:\/\/doi.org\/ 10.1007\/s11060-025-05197-5","DOI":"10.1007\/s11060-025-05197-5"},{"key":"ref59","doi-asserted-by":"crossref","unstructured":"60.\tArmstrong AE, Belzberg AJ, Crawford JR, Hirbe, AC, Wang J. Treatment decisions and the use of MEK inhibitors for children with neurofibromatosis type 1-related plexiform neurofibromas. BMC Cancer. 2023;23:553. https:\/\/doi.org\/ 10.1186\/s12885-023-10996-y","DOI":"10.1186\/s12885-023-10996-y"},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"61.\tKorf BR. Plexiform neurofibromas. Am J Med Genet. 1999;89:31\u201337. https:\/\/doi.org\/10.1002\/(sici)1096- 8628(19990326)89:1<31::aid-ajmg7>3.0.co;2-w","DOI":"10.1002\/(SICI)1096-8628(19990326)89:1<31::AID-AJMG7>3.0.CO;2-W"},{"key":"ref61","doi-asserted-by":"crossref","unstructured":"62.\tRadtke HB, Berger A, Skelton T, et al. Neurofibromatosis type 1 (NF1): addressing the transition from pediatric to adult care. Pediatric Health Med Ther. 2023;14:19\u201332. https:\/\/doi.org\/10.2147\/PHMT.S362679","DOI":"10.2147\/PHMT.S362679"},{"key":"ref62","doi-asserted-by":"crossref","unstructured":"63.\tWhite PH, Cooley WC, Transitions Clinical Report Authoring Group, et al. Supporting the health care transition from adolescence to adulthood in the medical home. Pediatrics. 2018;142:e20182587. https:\/\/doi.org\/10.1542\/peds.2018- 2587","DOI":"10.1542\/peds.2018-2587"},{"key":"ref63","doi-asserted-by":"crossref","unstructured":"64.\tLalvani S, Brown RM. Neurofibromatosis type 1: optimizing management with a multidisciplinary approach. J Multidiscip Healthc. 2024;17:1803\u20131817. https:\/\/doi.org\/10.2147\/JMDH.S362791","DOI":"10.2147\/JMDH.S362791"},{"key":"ref64","doi-asserted-by":"crossref","unstructured":"65.\tGoetsch Weisman A, Haws T, Lee J, et al. Transition readiness assessment in adolescents and young adults with neurofibromatosis type 1 (NF1). Compr Child Adolesc Nurs. 2023;46:223\u2013239. https:\/\/doi.org\/10.1080\/24694193.2020.1 806402","DOI":"10.1080\/24694193.2020.1806402"},{"key":"ref65","doi-asserted-by":"crossref","unstructured":"66.\tSiegel A, Lockridge R, Struemph KL, et al. Perceived transition readiness among adolescents and young adults with neurofibromatosis type 1 and plexiform neurofibromas: a cross-sectional descriptive study. J Pediatr Psychol. 2024;49:383\u2013391. https:\/\/doi.org\/10.1093\/jpepsy\/jsae006","DOI":"10.1093\/jpepsy\/jsae006"},{"key":"ref66","unstructured":"67.\tSociedad Espa\u00f1ola de Calidad Asistencial. Norma para la certificaci\u00f3n de la atenci\u00f3n a los pacientes con neurofibromatosis tipo 1 (NF1). https:\/\/calidadasistencial.es\/wp-content\/uploads\/2024\/04\/Libro_ NEUROFIBROMATOSIS-Tipo-1-definitivo-version-web.pdf. Accessed August 3, 2026."},{"key":"ref67","unstructured":"68.\tSalvador H, Morales M, Duat A, et al. Bridging the Gap. Recomendaciones para la transici\u00f3n de los pacientes con neurofibromatosis tipo 1. Proyecto NF1 Transition. Barcelona, Spain: Alexion Pharma Spain S.L.U. and GOC Health Consulting; 2025."},{"key":"ref68","doi-asserted-by":"crossref","unstructured":"69.\tVinent JL, Passos J, Aguilera A, et al. Characteristics of patients with neurofibromatosis and patient and caregiver perspectives on the impact of the disease and its clinical management in Spain and Portugal. J Rare Dis. 2025;4:27. https:\/\/doi.org\/10.1007\/s44162-025-00089-8","DOI":"10.1007\/s44162-025-00089-8"}],"container-title":["Drugs in Context"],"original-title":[],"link":[{"URL":"https:\/\/www.drugsincontext.com\/wp-content\/uploads\/2026\/09\/dic.2026-6-6.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T08:05:39Z","timestamp":1790150739000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.drugsincontext.com\/standalone-nf1-guiding-the-transition-from-paediatric-to-adult-care"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,23]]},"references-count":69,"URL":"https:\/\/doi.org\/10.7573\/dic.2026-6-6","relation":{},"ISSN":["1740-4398","1740-4398"],"issn-type":[{"value":"1740-4398","type":"print"},{"value":"1740-4398","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,23]]},"article-number":"dic.2026-6-6"}}